Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans
Asian Pacific Journal of Allergy and Immunology · 2025
DOI: 10.12932/ap-201220-1019 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Tae-Bin Won und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Cyproheptadine, Rhinitis, Allergic, Perennial. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: The efficacy of rupatadine for the treatment of AR has been confirmed in numerous clinical studies, however there are very few studies on asian patients. OBJECTIVE: To assess the safety and efficacy of rupatadine fumarate in the treatment of Korean perennial allergic rhinitis (PAR) patients. METHODS: A multicenter, double-blind, randomized, placebo-controlled, comparative study of rupatadine fumarate and bepotastine besilate was conducted. Each group was administered rupatadine, bepotastine or placebo for 4 weeks. Primary parameters for efficacy included morning and evening symptom reduction from baseline at 4 weeks. Treatment safety and tolerability were evaluated according to a self-reported incidence and type of adverse events at each follow up visit. RESULTS: Rupatadine showed a significant reduction in symptoms at morning and evening evaluations, in both 5TSS (-5.69, P < 0.0006) and 4NTSS (-4.74, P < 0.0015) compared to placebo. There was a significant reduction from baseline for 5TSS (-65.4%, P = 0.002) and 4NTSS (-63.7%, P = 0.003) with rupatadine compared with placebo. At evening evaluations, there were significant reductions of 5TSS (-63.2%, P = 0.009) and 4NTSS (-61.6%, P = 0.013) for the rupatadine group. Compared with bepotastine, rupatadine showed greater reduction in the morning symptoms at 4 weeks. When individual symptoms were assessed with 12-hour reflective mean daily symptom score, rupatadine showed better efficacy than placebo in sneezing (P = 0.016) and rhinorrhea (P = 0.097). The rate of adverse events showed no statistical significance. CONCLUSIONS: Rupatadine is a safe and effective treatment option for Korean PAR patients and possibly a better choice over bepotastine for controlling morning symptom.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Otorhinolaryngology-Head & Neck Surgery, Seoul National University Hospital, Seoul, Korea.
- Department of Otorhinolaryngology-Head & Neck Surgery, Hanyang University Guri Hospital, Guri, Korea.
- Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Konkuk University, Seoul, Korea.
- Department of Otorhinolaryngology, Inha University, Incheon, Korea.
- Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Zitieren
APA
Won, T. B., Kim, H. G., Kim, J. W., Kim, J. K., Kim, Y. H., Kim, S. W., Kim, H. Y., Kim, D. W., Kim, S. W., Kim, C. H., & Rhee, C. S. (2025). Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-201220-1019
Vancouver
Won TB, Kim HG, Kim JW, Kim JK, Kim YH, Kim SW, et al. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-201220-1019
BibTeX
@article{Won2025,
author = {Won, Tae-Bin and Kim, Hyung Gu and Kim, Jeong-Whun and Kim, Jin Kook and Kim, Young Hyo and Kim, Soo Whan and Kim, Hyo Yeol and Kim, Dae Woo and Kim, Sung Wan and Kim, Chang-Hoon and Rhee, Chae-Seo},
title = {Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2025},
doi = {10.12932/ap-201220-1019}
}
EUVIMED